Modeling heart failure by induced pluripotent stem cell-derived organoids

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Stem Cell Biology

Background:

• Traditional 2D models lack the complexity to fully represent cardiac tissue.
• Heart failure (HF) involves intricate cellular and structural changes, necessitating advanced in vitro models.

Purpose of the Study:

• To create self-assembled, scaffold-free cardiac organoids from induced pluripotent stem cells (iPSCs).
• To establish an in vitro model that simulates key pathological aspects of heart failure.
• To evaluate the efficacy of nutraceuticals in mitigating HF-induced changes.

Main Methods:

• Cardiac organoid generation from iPSCs.
• Induction of heart failure features using endothelin-1 (ET-1) treatment.
• Gene expression analysis (OCT4, NANOG, TNNT2, DES, ANP, BNP, ACTA1), microRNA profiling, functional contractility assays, and protein aggregation analysis (Thioflavin T staining, fluorescence assay, filter trap assay).

Main Results:

• Validated cardiac differentiation of organoids.
• ET-1 treatment successfully induced HF markers, including ANP, BNP, ACTA1 upregulation, and reduced contractility.
• Demonstrated significant protein aggregation post-ET-1 treatment.
• Nutraceutical co-administration mitigated ET-1-induced pathological effects.

Conclusions:

• The ET-1-stimulated cardiac organoid model is a valuable platform for studying heart failure mechanisms.
• This model facilitates the in vitro evaluation of novel therapeutic strategies for heart failure.
• Scaffold-free cardiac organoids offer a robust system for disease modeling.